Chemotherapy for advanced pancreatic cancer

Best Practice and Research: Clinical Gastroenterology

Volumn 20, Issue 2, 2006, Pages 327-348

  Chua, Yu Jo ^a   Cunningham, David ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Adenocarcinoma; Advanced; Biological therapy; Cancer; Capecitabine; Chemotherapy; Gemcitabine; Metastatic; Oxaliplatin; Pancreas; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CIPROFLOXACIN; CISPLATIN; CYTOTOXIC AGENT; DEOXYCYTIDINE KINASE; DNA; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; EPIRUBICIN; ERLOTINIB; EXATECAN; FLUOROURACIL; FOLIC ACID ANTAGONIST; FOLINIC ACID; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; MITOMYCIN C; NEW DRUG; OXALIPLATIN; PACLITAXEL; PEMETREXED; PLATINUM DERIVATIVE; PLEVITREXED; RALTITREXED; RUBITECAN; TAXANE DERIVATIVE; UNINDEXED DRUG;

ACNE; ADVANCED CANCER; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; BLEEDING DISORDER; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DIARRHEA; DISEASE EXACERBATION; DNA SYNTHESIS INHIBITION; DRUG COST; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG FATALITY; DRUG POTENTIATION; DRUG TARGETING; DYSESTHESIA; ENZYME INHIBITION; FATIGUE; FEBRILE NEUTROPENIA; FEVER; FLU LIKE SYNDROME; HAND FOOT SYNDROME; HEALTH CARE ORGANIZATION; HUMAN; INTESTINE PERFORATION; LARYNX DISORDER; LETHARGY; META ANALYSIS; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OTOTOXICITY; PANCREAS CANCER; PATIENT CARE; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SENSORY NEUROPATHY; SKIN TOXICITY; STANDARDIZATION; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; UNITED KINGDOM; VOMITING;

EID: 33645026018     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpg.2005.10.003     Document Type: Article

References (100)

1. D. Cunningham I. Chau D. Stocken et. al. Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer Eur J Cancer Suppl 4 2005 abstr PS11
2. R.B. Ballard J.P. Hoffman M.C. Guttman et. al. How accurate is size measurement of pancreas cancer masses by computed axial tomography (CT) scanning? Am Surg 61 8 1995 686-691
3. B. Glimelius K. Hoffman P.O. Sjoden et. al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer Ann Oncol 7 6 1996 593-600
4. K.R. Palmer M. Kerr G. Knowles et. al. Chemotherapy prolongs survival in inoperable pancreatic carcinoma Br J Surg 81 6 1994 882-885
5. C.N. Mallinson M.O. Rake J.B. Cocking et. al. Chemotherapy in pancreatic cancer: Results of a controlled, prospective, randomised, multicentre trial Br Med J 281 6255 1980 1589-1591
6. M.C. Fung S. Takayama H. Ishiguro et. al. Chemotherapy for advanced or metastatic pancreatic cancer: Analysis of 43 randomized trials in 3 decades (1974-2002) Gan To Kagaku Ryoho 30 8 2003 1101-1111
7. J. Carmichael U. Fink R.C. Russell et. al. Phase II study of gemcitabine in patients with advanced pancreatic cancer Br J Cancer 73 1 1996 101-105
8. E.S. Casper M.R. Green D.P. Kelsen et. al. Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas Invest New Drugs 12 1 1994 29-34
9. M.L. Rothenberg M.J. Moore M.C. Cripps et. al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer Ann Oncol 7 4 1996 347-353
10. H.A. Burris III M.J. Moore J. Andersen et. al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial J Clin Oncol 15 6 1997 2403-2413
11. H.S. Hochster Newer approaches to gemcitabine-based therapy of pancreatic cancer: Fixed-dose-rate infusion and novel agents Int J Radiat Oncol Biol Phys 56 4 supplement 2003 24-30
12. N. Touroutoglou D. Gravel M.N. Raber et. al. Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors Ann Oncol 9 9 1998 1003-1008
13. M. Tempero W. Plunkett V. Ruiz Van Haperen et. al. Randomized phase II comparison of dose-intense gemcitabine: Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma J Clin Oncol 21 18 2003 3402-3408
14. S. Cascinu L. Frontini R. Labianca et. al. A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD) Ann Oncol 11 10 2000 1309-1311
15. C. Louvet T. Andre G. Lledo et. al. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: Final results of a GERCOR multicenter phase II study J Clin Oncol 20 6 2002 1512-1518
16. J.A. DeCaprio R.J. Mayer R. Gonin et. al. Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: Results of a phase II trial J Clin Oncol 9 12 1991 2128-2133
17. J. Crown E.S. Casper J. Botet et. al. Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma J Clin Oncol 9 9 1991 1682-1686
18. R. Hansen E. Quebbeman P. Ritch et. al. Continuous 5-fluorouracil (5FU) infusion in carcinoma of the pancreas: A phase II study Am J Med Sci 295 2 1988 91-93
19. N. Maisey I. Chau D. Cunningham et. al. Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer J Clin Oncol 20 14 2002 3130-3136
20. M. Hidalgo D. Castellano L. Paz-Ares et. al. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer J Clin Oncol 17 2 1999 585-592
21. E. Matano P. Tagliaferri A. Libroia et. al. Gemcitabine combined with continuous infusion 5-fluorouracil in advanced and symptomatic pancreatic cancer: A clinical benefit-oriented phase II study Br J Cancer 82 11 2000 1772-1775
22. J.E. Kurtz F. Kohser S. Negrier et. al. Gemcitabine and protracted 5-FU for advanced pancreatic cancer. A phase II study Hepatogastroenterology 47 35 2000 1450-1453
23. H. Oettle M. Arning U. Pelzer et. al. A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer Ann Oncol 11 10 2000 1267-1272
24. D.P. Rauch C.A. Maurer S. Aebi et. al. Activity of gemcitabine and continuous infusion fluorouracil in advanced pancreatic cancer Oncology 60 1 2001 43-48
25. C. Louvet T. Andre P. Hammel et. al. Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM) Ann Oncol 12 5 2001 675-679
26. C. Barone A. Cassano D.C. Corsi et. al. Weekly gemcitabine and 24-hour infusional 5-fluorouracil in advanced pancreatic cancer: A phase I-II study Oncology 64 2 2003 139-145
27. J.D. Berlin S. Adak D.J. Vaughn et. al. A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: An Eastern Cooperative Oncology Group Study (E3296) Oncology 58 3 2000 215-218
28. A. Marantz S. Jovtis E. Almira et. al. Phase II study of gemcitabine, 5-fluorouracil, and leucovorin in patients with pancreatic cancer Semin Oncol 28 3 supplement 10 2001 44-49
29. P. Correale S. Messinese S. Marsili et. al. A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid Br J Cancer 89 2 2003 239-242
30. F. Di Costanzo P. Carlini L. Doni et. al. Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: A randomised phase II trial of the Italian oncology group for clinical research (GOIRC) Br J Cancer 93 2 2005 185-189
31. J.D. Berlin P. Catalano J.P. Thomas et. al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297 J Clin Oncol 20 15 2002 3270-3275
32. H. Riess A. Helm M. Niedergethmann et. al. A randomised, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer J Clin Oncol 23 16s June 1 supplement 2005 310s [abstr LBA4009]
33. T.H. Cartwright A. Cohn J.A. Varkey et. al. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer J Clin Oncol 20 1 2002 160-164
34. V. Hess M. Salzberg M. Borner et. al. Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: A phase I/II trial J Clin Oncol 21 1 2003 66-68
35. W. Scheithauer B. Schull H. Ulrich-Pur et. al. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: A randomized phase II trial Ann Oncol 14 1 2003 97-104
36. V. Heinemann T. Hoehler A. Seipelt et. al. Capecitabine plus Oxaliplatin (CapOx) versus Capecitabine plus Gemcitabine (CapGem) versus Gemcitabine plus Oxaliplatin (GemOx): A randomized phase II trial in advanced pancreatic cancer J Clin Oncol 23 16s June 1 supplement 2005 315s [abstr 4030]
37. R. Herrmann G. Bodoky T. Ruhstaller et. al. Gemcitabine (G) plus Capecitabine (C) versus G alone in locally advanced or metastatic pancreatic cancer. A randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG) J Clin Oncol 23 16s June 1 supplement 2005 310s [abstr LBA4010]
38. H.L. Kindler The pemetrexed/gemcitabine combination in pancreatic cancer Cancer 95 4 supplement 2002 928-932
39. K.D. Miller J. Picus C. Blanke et. al. Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer Ann Oncol 11 1 2000 101-103
40. A.A. Adjei C. Erlichman J.A. Sloan et. al. Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors J Clin Oncol 18 8 2000 1748-1757
41. H.L. Kindler W. Duganm H. Hochster et. al. Clinical outcome in patients (pts) with advanced pancreatic cancer treated with pemetrexed/ gemcitabine Proc Am Soc Clin Oncol 2002 [abstr 499]
42. H. Oettle D. Richards R.K. Ramanathan et. al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer Ann Oncol 16 10 2005 1639-1645
43. J.A. Wils T. Kok D.J. Wagener et. al. Activity of cisplatin in adenocarcinoma of the pancreas Eur J Cancer 29A 2 1993 203-204
44. T. Brodowicz R.M. Wolfram W.J. Kostler et. al. Phase II study of gemcitabine in combination with cisplatin in patients with locally advanced and/or metastatic pancreatic cancer Anticancer Drugs 11 8 2000 623-628
45. V. Heinemann H. Wilke H.G. Mergenthaler et. al. Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer Ann Oncol 11 11 2000 1399-1403
46. P.A. Philip M.M. Zalupski V.K. Vaitkevicius et. al. Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma Cancer 92 3 2001 569-577
47. S. Cascinu R. Labianca V. Catalano et. al. Weekly gemcitabine and cisplatin chemotherapy: A well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD) Ann Oncol 14 2 2003 205-208
48. V. Heinemann D. Quietzsch F. Gieseler et. al. A phase III trial comparing gemcitabine plus cisplatin vs. gemcitabine alone in advanced pancreatic carcinoma Proc Am Soc Clin Oncol 22 2003 250 [abstr 1003]
49. G. Colucci F. Giuliani V. Gebbia et. al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: A prospective, randomized phase III study of the Gruppo Oncologia dell'italia Meridionale Cancer 94 4 2002 902-910
50. M. Nicolson A. Webb D. Cunningham et. al. Cisplatin and protracted venous infusion 5-fluorouracil (CF)-good symptom relief with low toxicity in advanced pancreatic carcinoma Ann Oncol 6 8 1995 801-804
51. M. Ducreux P. Rougier J.P. Pignon et. al. A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma Ann Oncol 13 8 2002 1185-1191
52. S.R. Alberts P.M. Townley R.M. Goldberg et. al. Gemcitabine and oxaliplatin for patients with advanced or metastatic pancreatic cancer: a North Central Cancer Treatment Group (NCCTG) phase I study Ann Oncol 13 4 2002 553-557
53. S.R. Alberts P.M. Townley R.M. Goldberg et. al. Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: A North Central Cancer Treatment Group phase II study Ann Oncol 14 4 2003 580-585
54. C. Louvet R. Labianca P. Hammel et. al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a GERCOR and GISCAD phase III trial J Clin Oncol 23 15 2005 3509-3516
55. M. Ducreux E. Mitry M. Ould-Kaci et. al. Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients Ann Oncol 15 3 2004 467-473
56. D.J. Wagener H.E. Verdonk L.Y. Dirix et. al. Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study Ann Oncol 6 2 1995 129-132
57. C.M. Rocha Lima D. Savarese H. Bruckner et. al. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer J Clin Oncol 20 5 2002 1182-1191
58. C.M. Rocha Lima M.R. Green R. Rotche et. al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate J Clin Oncol 22 18 2004 3776-3783
59. D. D'Adamo L. Hammond R. Donehower et. al. A randomized phase III study comparing gemcitabine+pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer Proc Am Soc Clin Oncol 20 2001 [abstr 532]
60. P. Cheverton H. Friess C. Andras et. al. Phase III results of exatecan (DX-8951f) versus gemcitabine (Gem) in chemotherapy-naïve patients with advanced pancreatic cancer (APC) J Clin Oncol 23 14s July 15 supplement 2004 [abstr LBA4005]
61. E.M. O'Reilly G.K. Abou-Alfa R. Letourneau et. al. A randomized phase III trial of DX-8951f (exatecan mesylate; DX) and gemcitabine (GEM) vs. gemcitabine alone in advanced pancreatic cancer (APC) J Clin Oncol 23 14s July 15 supplement 2004 [abstr LBA4006]
62. J.S. Stehlin B.C. Giovanella E.A. Natelson et. al. A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer Int J Oncol 14 5 1999 821-831
63. M.M. Konstadoulakis P.T. Antonakis B.G. Tsibloulis et. al. A phase II study of 9-nitrocamptothecin in patients with advanced pancreatic adenocarcinoma Cancer Chemother Pharmacol 48 5 2001 417-420
64. S. Okada Y. Sakata S. Matsuno et. al. Phase II study of docetaxel in patients with metastatic pancreatic cancer: A Japanese cooperative study. Cooperative Group of Docetaxel for Pancreatic Cancer in Japan Br J Cancer 80 3-4 1999 438-443
65. N. Androulakis C. Kourousis M.A. Dimopoulos et. al. Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: A multicenter phase II study J Clin Oncol 17 6 1999 1779-1785
66. P. Rougier A. Adenis M. Ducreux et. al. A phase II study: Docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma Eur J Cancer 36 8 2000 1016-1025
67. R. Lenzi S. Yalcin D.B. Evans et. al. Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy Cancer Invest 20 4 2002 464-472
68. S. Cascinu G. Gasparini V. Catalano et. al. A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD) Ann Oncol 10 11 1999 1377-1379
69. G.P. Stathopoulos D. Mavroudis N. Tsavaris et. al. Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: A phase II study of the Greek Cooperative Group for Pancreatic Cancer Ann Oncol 12 1 2001 101-103
70. D.P. Ryan M.H. Kulke C.S. Fuchs et. al. A phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma Cancer 94 1 2002 97-103
71. R.C. Shepard D.E. Levy J.D. Berlin et. al. Phase II study of gemcitabine in combination with docetaxel in patients with advanced pancreatic carcinoma (E1298). A trial of the Eastern Cooperative Oncology Group Oncology 66 4 2004 303-309
72. R.P. Whitehead J. Jacobson T.D. Brown et. al. Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: A Southwest Oncology Group study J Clin Oncol 15 6 1997 2414-2419
73. A. Jacobs A. Planting D. Ferry et. al. Efficacy of DHA-paclitaxel (TXP) in pancreatic cancer Proc Am Soc Clin Oncol 22 2003 272 [abstr 1090]
74. R. Pazdur N.J. Meropol E.S. Casper et. al. Phase II trial of ZD1694 (tomudex) in patients with advanced pancreatic cancer Invest New Drugs 13 4 1996 355-358
75. E. Kralidis S. Aebi H. Friess et. al. Activity of raltitrexed and gemcitabine in advanced pancreatic cancer Ann Oncol 14 4 2003 574-579
76. S. Mani J.W. Kugler D.F. Sciortino et. al. Phase II trial of uracil/ tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma: A University of Chicago phase II consortium study Ann Oncol 9 9 1998 1035-1037
77. J. Feliu M.P. Lopez Alvarez M.A. Jaraiz et. al. Phase II trial of gemcitabine and UFT modulated by leucovorin in patients with advanced pancreatic carcinoma. The ONCOPAZ Cooperative Group Cancer 89 8 2000 1706-1713
78. J. Feliu R. Mel P. Borrega et. al. Phase II study of a fixed dose-rate infusion of gemcitabine associated with uracil/tegafur in advanced carcinoma of the pancreas Ann Oncol 13 11 2002 1756-1762
79. B. Neri G. Cini L. Doni et. al. Weekly gemcitabine plus epirubicin as effective chemotherapy for advanced pancreatic cancer: A multicenter phase II study Br J Cancer 87 5 2002 497-501
80. M. Reni S. Cordio C. Milandri et. al. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial Lancet Oncol 6 6 2005 369-376
81. M. Reni P. Passoni M.G. Panucci et. al. Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma J Clin Oncol 19 10 2001 2679-2686
82. D. Smith N. Gallagher A phase II/III study comparing intravenous ZD9331 with gemcitabine in patients with pancreatic cancer Eur J Cancer 39 10 2003 1377-1383
83. H. Oettle U. Pelzer J. Stieler et. al. Oxaliplatin/folinic acid/ 5-fluorouracil [24h] (OFF) plus best supportive careversus best supportive care alone (BSC) in second-line therapy ofgemcitabine-refractory advanced pancreatic cancer (CONKO 003) J Clin Oncol 23 16s June 1 supplement 2005 315s [abstr 4031]
84. H.A. Burris 3rd S. Rivkin R. Reynolds et. al. Phase II trial of oral rubitecan in previously treated pancreatic cancer patients Oncologist 10 3 2005 183-190
85. S.W. Papish R. Ramanathan J. Pincus et. al. Patients rescued by crossover to rubitecan in phase III study of rubitecan capsules versus 5-FU in pancreatic cancer J Clin Oncol 23 16s June 1 supplement 2005 349s [abstr 4165]
86. A.D. Jacobs H.A. Burris S. Rivkin et. al. A randomized phase III study of rubitecan (ORA) vs. best choice (BC) in 409 patients with refractory pancreatic cancer report from a North-American multi-center study J Clin Oncol 22 14s July 15 supplement 2004 315 [abstr 4013]
87. H. Ulrich-Pur M. Raderer G. Verena Kornek et. al. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma Br J Cancer 88 8 2003 1180-1184
88. J.L. Van Laethem M. Polus R. Marechal et. al. Gemcitabine and oxaliplatine (GEMOX) in gemcitabine-refractory advanced pancreatic cancer: A phase II study J Clin Oncol 23 14s July 15 supplement 2004 342 [abstr 4119]
89. S.S. Ng M.S. Tsao T. Nicklee et. al. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma Mol Cancer Ther 1 10 2002 777-783
90. M. Hidalgo L.L. Siu J. Nemunaitis et. al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies J Clin Oncol 19 13 2001 3267-3279
91. M.J. Moore D. Goldstein J. Hamm et. al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG] J Clin Oncol 23 16s June 1 supplement 2005 1s [abstr]
92. L. Blaszkowsky M.H. Kulke D.P. Ryan et. al. A phase II study of erlotinib (tarveca) in combination with capecitabine in previously treated patients with metastatic pancreatic cancer J Clin Oncol 23 16s June 1 supplement 2005 332s [abstr 4099]
93. H.Q. Xiong A. Rosenberg A. LoBuglio et. al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: A multicenter phase II trial J Clin Oncol 22 13 2004 2610-2616
94. H.L. Kindler G. Friberg W.M. Stadler et. al. Bevacizumab (B) plus gemcitabine (G) in patient (pts) with advanced pancreatic cancer (PC): updated results of a multi-center phase II trial J Clin Oncol 23 14s July 15 supplement 2004 314 [abstr 4009]
95. S.J. Cohen L. Ho S. Ranganathan et. al. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma J Clin Oncol 21 7 2003 1301-1306
96. E. Van Cutsem H. van de Velde P. Karasek et. al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer J Clin Oncol 22 8 2004 1430-1438
97. J.D. Evans A. Stark C.D. Johnson et. al. A phase II trial of marimastat in advanced pancreatic cancer Br J Cancer 85 12 2001 1865-1870
98. S.R. Bramhall A. Rosemurgy P.D. Brown et. al. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: A randomized trial J Clin Oncol 19 15 2001 3447-3455
99. S.R. Bramhall J. Schulz J. Nemunaitis et. al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer Br J Cancer 87 2 2002 161-167
100. M.J. Moore J. Hamm J. Dancey et. al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 21 17 2003 3296-3302